Moderna and Merck's Melanoma Therapy Meets Primary Goal in Phase 3 Trial
Shares of Moderna (NASDAQ:MRNA) surged nearly 93% to $121.76, while Merck & Co. (NYSE:MRK) rose by 7%, following the announcement that their personalized mRNA cancer therapy met its primary endpoint in a Phase 3 trial for melanoma. The combination of Moderna's Intismeran Autogene and Merck’s Keytruda showed statistically significant improvements in recurrence-free survival compared to Keytruda alone. The INTerpath-001 trial involved over 1,100 patients with high-risk stage IIB-IV melanoma who had undergone surgery. The results validate Moderna's long-term investment in personalized mRNA cancer therapies and could redefine treatment for certain cancers. Merck’s Dean Y. Li highlighted the potential of individualized neoantigen therapy to transform care for resected melanoma patients.
Topics: cancer treatment Keytruda melanoma mRNA therapy stock surge